Fatma Onmus

Clinical Bioinformatician

  • Current Role

    Current Role

    As a clinical bioinformation for the Clinical and Translational Research Informatics Branch, I’m responsible for the oversight of the CIDC part of the CIMAC-CIDC network (CIDC being the “Cancer Immunologic Data Commons,” while CIMAC stands for “Cancer Immune Monitoring and Analysis Centers”). This network addresses the critical importance of improving the management of cancer patients receiving immunotherapy by identifying biomarkers for optimizing immunotherapeutic strategies. The CIMAC-CIDC network involves a collaborative effort among various stakeholders, such as NCI, Clinical Trial Teams, CIMACs, the Partnership for Accelerating Cancer Therapies collaboration, and Foundation NIH. Together, we can collect, analyze, and share the data from various clinical trials that use analytically validated and standardized platforms.

  • Projects

    Projects

    Photo of a doctor sitting next to a younger woman. The doctor is speaking to the woman and the woman is looking at the doctor and smiling.

    Molecular Analysis for Therapy Choice (MATCH)

    Enrolls patients to determine whether treating cancer based on their genome is effective.
  • Publications

    Publications

    View Fatma’s PubMed Summary
  • Background

    Background

    Education

    • Graduate Certificate Bioinformatics, University of Maryland Global Campus
    • M.S., Biology, Ege Üniversitesi (Turkey)
    • B.S., Biology, Ege Üniversitesi  (Turkey)

    Previous Work

    • Biologist, U.S. Department of Health and Human Services, Food and Drug Administration (FDA)
    • Senior Scientific Computer Engineer, Science Applications International Corporation
    • Bioinformatician, Contractor for Walter Reed Army Institute of Research
    • Research Associate/Lab Manager, J. Craig Venter Institute
    • Supervisor/Project Manager, Gene Logic
    • Associate Scientist, Metrigenix
    • Associate Scientist, Digene Corporation

    Recent Awards

    1. 2022 FDA Commissioner’s Special Citation (Memorial Sloan Kettering OncoKB Database Team), for outstanding collaboration that led to the recognition of a tumor biomarker database, which supports the agency’s precision medicine initiatives
    2. 2022 FDA Commissioner’s Special Citation (Paige Prostate De Novo Review Team), for excellent collaboration and coordination that led to the authorization of the first artificial intelligence-based software in digital pathology
    3. 2021 FDA Commissioner’s Special Citation (EUA Personal Protective Equipment Response Team), for outstanding dedication and work defending public health during the COVID-19 pandemic by tirelessly working to provide personal protective equipment for emergency use